News from the WV Board of Veterinary Medicine

News

  • Drug Diversion Continuing Education Statement:

    3/24/2024
    The 2023 Legislature passed a law that will be implemented this renewal cycle (2024) for pharmacists regarding the Drug Diversion Continuing Education (CE) requirement.  This law update only requires pharmacists to complete the Drug Diversion CE one time within one year after initial licensure.  
    • Therefore, if you have reported Drug Diversion CE to the WV BOP during a licensure renew before 2024 you DO NOT need to report the Drug Diversion CE requirement in 2024. 
    • Licensees who are renewing for the first time and have never reported the 2-hour board-approved Drug Diversion CE requirement to the WVBOP are required to report it this year in 2024 at license renewal. 
    Questions should be sent to Krista Capehart, PharmD, Director of Professional and Regulatory Affairs at krista.d.capehart@wv.gov.
  • UPDATED 5-2-23: WVBOP Statement on Semaglutide Compounding

    5/2/2023
    The West Virginia Board of Pharmacy (Board) staff has received inquiries concerning the compounding of semaglutide. This topic has become very prominent across the nation, as the medication has gained notoriety for various reasons. Semaglutide is, of course, a commercially available drug product marketed as Ozempic™ for treating diabetes and as Wegovy™ for weight loss. The Board of Pharmacy in both Mississippi and North Carolina have already issued statements, and the Boards of Pharmacy in other states appear ready to make similar statements.
  • WV BOP Statement on Semaglutide Compounding

    4/21/2023
    The West Virginia Board of Pharmacy (Board) staff has received inquiries concerning the compounding of semaglutide. This topic has become very prominent across the nation, as the medication has gained notoriety for various reasons. Semaglutide is, of course, a commercially available drug product marketed as OzempicTM for treating diabetes and as WegovyTM for weight loss. The Board of Pharmacy in both Mississippi and North Carolina have already issued statements, and the Boards of Pharmacy in other states appear ready to make similar statements. The federal Food Drug & Cosmetic Act prohibits pharmacies from compounding “drug products that are essentially copies of a commercially available drug product.” In general, compounding pharmacies may not compound semaglutide, a commercially available drug product.
  • CDC Updates COVID19 Vaccine Recommendations

    4/20/2023
    After the FDA updated the Emergency Use Authorization for the mRNA COVID-19 bivalent vaccines, the CDC issued new, simplified recommendations yesterday and effective now. Their complete guidance can be found here. The CDC is working to update the Interim COVID-19 Clinical Considerations and this will be updated as soon as possible. We will add them and a link to the WV BOP FAQ section as soon as they are available. See below for a summary of the new guidelines.
Page Updated: 7/27/2017 2:05:32 PM